EASTONBIOPHARMACEUTICALS(SH:688513)2023-04-27 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥277,853,183.77, representing a year-on-year increase of 3.31%[5] - The net profit attributable to shareholders for the same period was ¥60,985,871.41, reflecting a growth of 13.35% compared to the previous year[5] - The basic earnings per share for Q1 2023 stood at ¥0.51, which is an increase of 13.33% year-on-year[6] - The net profit for Q1 2023 was CNY 60,985,871.41, representing an increase of 13.8% compared to CNY 53,801,911.59 in Q1 2022[19] - The operating profit for Q1 2023 was CNY 68,278,212.94, up from CNY 57,338,282.15 in the same period last year, indicating a growth of 19.4%[22] - The total operating expenses decreased to CNY 244,172,808.16 from CNY 282,959,361.73 in Q1 2022, a reduction of 13.7%[22] Research and Development - Research and development expenses totaled ¥51,336,628.31, accounting for 18.48% of operating revenue, a decrease of 1.34 percentage points from the previous year[6] - Research and development expenses increased to CNY 50,088,561.76, compared to CNY 45,192,135.02 in Q1 2022, reflecting an increase of 6.4%[22] Cash Flow and Assets - The net cash flow from operating activities was ¥32,933,694.58, showing a decline of 11.54% compared to the same period last year[5] - The cash flow from operating activities was CNY 32,933,694.58, a decrease from CNY 37,228,404.83 in the previous year, down by 11.5%[22] - The cash flow from investment activities showed a net outflow of CNY 289,811,019.34, improving from a net outflow of CNY 512,688,220.48 in Q1 2022[23] - Cash and cash equivalents decreased to RMB 620,514,361.50 from RMB 830,966,815.87 at the end of 2022, a decline of about 25.3%[13] - The company reported a cash and cash equivalents balance of CNY 614,284,188.64 at the end of Q1 2023, compared to CNY 590,296,812.64 at the end of Q1 2022, an increase of 4.0%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period was 4,643[9] - The largest shareholder, Wang Ying, holds 41,900,000 shares, representing 34.89% of the total shares[9] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,098,765,523.95, an increase of 2.69% from the end of the previous year[6] - Current assets as of March 31, 2023, totaled RMB 1,742,813,162.60, compared to RMB 1,709,122,350.80 at the end of 2022, reflecting an increase of approximately 1.96%[13] - Total liabilities as of March 31, 2023, were RMB 592,973,210.53, up from RMB 573,080,516.96 at the end of 2022, representing an increase of about 3.2%[15] - Non-current assets totaled RMB 1,355,952,361.35, an increase from RMB 1,308,417,882.31 at the end of 2022, reflecting a growth of about 3.63%[14] - The company's retained earnings increased to RMB 881,245,083.61 from RMB 820,259,212.19 at the end of 2022, showing an increase of approximately 7.4%[15] Operating Costs - Total operating costs for Q1 2023 were RMB 226,451,481.30, slightly up from RMB 225,745,308.15 in Q1 2022, indicating a marginal increase of about 0.31%[17] - The company reported a net profit margin improvement, with total operating income growth outpacing total operating costs growth in Q1 2023[17] - The total revenue from operating activities was CNY 255,609,521.27, down from CNY 299,663,469.03 in Q1 2022, a decrease of 14.7%[22] Other Income - The company achieved other income of CNY 10,914,075.81, compared to CNY 6,027,818.28 in Q1 2022, marking an increase of 81.5%[22] - The company reported non-recurring gains of ¥14,655,333.08 for the period, after accounting for tax effects[7]